PathoQuest has entered into a definitive agreement to be acquired by Charles River Laboratories, enhancing biosafety testing solutions within the biopharmaceutical sector.

Target Company Overview

PathoQuest, headquartered in Paris, France, with an additional site in Wayne, Pennsylvania, is a pioneering company specializing in Next Generation Sequencing (NGS)-based biosafety testing. Founded with the support of Kurma Partners and the esteemed Pasteur Institute, PathoQuest has emerged as a global leader in its field, delivering critical services to pharmaceutical, biotech, and Contract Development and Manufacturing Organizations (CDMO) worldwide. Its proprietary iDTECT® platform is designed for advanced viral safety and genetic characterization testing, addressing the complex demands of modern biologic modalities including cell and gene therapies as well as vaccines.

Industry Overview

The biosafety testing industry, particularly in France, is undergoing rapid transformation driven by advancements in biopharmaceutical research. As the demand for innovative treatments accelerates, there is an increased focus on ensuring the safety and efficacy of biologic products. Given the emergence of new technologies and the evolving regulatory landscape, companies in this sector are required to implement faster and more reliable testing methods to comply with stringent safety standards.

France is recognized as a hub for biopharmaceutical development in Europe, supported by robust research institutions and a growing number of startups dedicated to advancing healthcare solutions. The partnership between i